Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| Yesterday 5:05 PM View:  | Mills Kenneth T. President and CEO Director | Regenxbio Inc. (RGNX) | 15-Apr-24 | Planned Option Sale | 15,000 | $18.19 | $272,871.00 | (4%) 423.04K to 408.04K | |
| Yesterday 5:05 PM View: | Mills Kenneth T. President and CEO Director | Regenxbio Inc. (RGNX) | 15-Apr-24 | Option Exercise | 15,000 | $3.76 | $56,400.00 | 4% 408.04K to 423.04K | |
| 21-Mar-24 5:20 PM View: | Vasista Vittal Chief Financial Officer | Regenxbio Inc. (RGNX) | 19-Mar-24 | Option Exercise | 20,041 | $3.76 | $75,354.20 | 9% 226.49K to 246.53K | |
| 18-Mar-24 5:03 PM View: | Mills Kenneth T. President and CEO Director | Regenxbio Inc. (RGNX) | 14-Mar-24 | Planned Option Sale | 15,000 | $21.86 | $327,942.00 | (4%) 423.04K to 408.04K | |
| 18-Mar-24 5:03 PM View: | Mills Kenneth T. President and CEO Director | Regenxbio Inc. (RGNX) | 14-Mar-24 | Option Exercise | 15,000 | $3.76 | $56,400.00 | 4% 408.04K to 423.04K | |
| 07-Mar-24 6:05 PM View: | Pakola Steve Chief Medical Officer | Regenxbio Inc. (RGNX) | 05-Mar-24 | Option Exercise | 12,878 | $22.25 | $286,536.00 | 12% 107.19K to 120.07K | |
| 07-Mar-24 6:05 PM View: | Pakola Steve Chief Medical Officer | Regenxbio Inc. (RGNX) | 05-Mar-24 | Planned Option Sale | 12,878 | $28.36 | $365,220.00 | (11%) 120.07K to 107.19K | |
| 16-Feb-24 6:28 PM View: | Mills Kenneth T. President and CEO Director | Regenxbio Inc. (RGNX) | 14-Feb-24 | Planned Option Sale | 15,000 | $16.76 | $251,349.00 | (4%) 423.04K to 408.04K | |
| 16-Feb-24 6:28 PM View: | Mills Kenneth T. President and CEO Director | Regenxbio Inc. (RGNX) | 14-Feb-24 | Option Exercise | 15,000 | $3.76 | $56,400.00 | 4% 408.04K to 423.04K | |
| 18-Jan-24 6:39 PM View: | Mills Kenneth T. President and CEO Director | Regenxbio Inc. (RGNX) | 16-Jan-24 | Planned Option Sale | 45,000 | $15.18 | $682,992.00 | (10%) 453.04K to 408.04K | |
| 18-Jan-24 6:39 PM View: | Mills Kenneth T. President and CEO Director | Regenxbio Inc. (RGNX) | 16-Jan-24 | Option Exercise | 45,000 | $3.76 | $169,200.00 | 11% 408.04K to 453.04K | |
| 04-Jan-24 4:23 PM View: | Pakola Steve Chief Medical Officer | Regenxbio Inc. (RGNX) | 03-Jan-24 | Sale (Planned) | 17,237 | $17.39 | $299,789.00 | (14%) 124.43K to 107.19K | |
| 04-Jan-24 4:17 PM View: | Vasista Vittal Chief Financial Officer | Regenxbio Inc. (RGNX) | 02-Jan-24 | Payment of Exercise | 4,534 | $17.95 | $81,385.30 | (2%) 231.03K to 226.49K | |
| 04-Jan-24 4:06 PM View: | Christmas Patrick J. Chief Legal Officer | Regenxbio Inc. (RGNX) | 02-Jan-24 | Payment of Exercise | 7,893 | $17.95 | $141,679.00 | (6%) 123.65K to 115.76K | |
| 04-Jan-24 4:07 PM View: | Mills Kenneth T. President and CEO Director | Regenxbio Inc. (RGNX) | 02-Jan-24 | Grant | 64,103 | -- | -- | 18% 355.29K to 419.39K | |
| 04-Jan-24 4:34 PM View: | Simpson Curran Chief Oper. & Tech. Officer | Regenxbio Inc. (RGNX) | 02-Jan-24 | Grant | 38,462 | -- | -- | 41% 92.98K to 131.45K | |
| 04-Jan-24 4:23 PM View: | Pakola Steve Chief Medical Officer | Regenxbio Inc. (RGNX) | 02-Jan-24 | Grant | 32,051 | -- | -- | 31% 102.76K to 134.81K | |
| 04-Jan-24 4:07 PM View: | Mills Kenneth T. President and CEO Director | Regenxbio Inc. (RGNX) | 02-Jan-24 | Payment of Exercise | 11,357 | $17.95 | $203,858.00 | (3%) 419.39K to 408.04K | |
| 04-Jan-24 4:22 PM View: | Danos Olivier Chief Scientific Officer | Regenxbio Inc. (RGNX) | 02-Jan-24 | Grant | 38,462 | -- | -- | 41% 94.8K to 133.26K | |
| 04-Jan-24 4:34 PM View: | Simpson Curran Chief Oper. & Tech. Officer | Regenxbio Inc. (RGNX) | 02-Jan-24 | Payment of Exercise | 8,120 | $17.95 | $145,754.00 | (6%) 131.45K to 123.33K | |
| 04-Jan-24 4:17 PM View: | Vasista Vittal Chief Financial Officer | Regenxbio Inc. (RGNX) | 02-Jan-24 | Grant | 16,026 | -- | -- | 7% 215.0K to 231.03K | |
| 04-Jan-24 4:06 PM View: | Christmas Patrick J. Chief Legal Officer | Regenxbio Inc. (RGNX) | 02-Jan-24 | Grant | 34,615 | -- | -- | 39% 89.04K to 123.65K | |
| 04-Jan-24 4:23 PM View: | Pakola Steve Chief Medical Officer | Regenxbio Inc. (RGNX) | 02-Jan-24 | Payment of Exercise | 10,385 | $17.95 | $186,411.00 | (8%) 134.81K to 124.43K | |
| 04-Jan-24 4:22 PM View: | Danos Olivier Chief Scientific Officer | Regenxbio Inc. (RGNX) | 02-Jan-24 | Payment of Exercise | 8,410 | $17.95 | $150,960.00 | (6%) 133.26K to 124.85K | |
| 21-Dec-23 1:38 PM View: | Mills Kenneth T. President and CEO Director | Regenxbio Inc. (RGNX) | 19-Dec-23 | Planned Option Sale | 45,000 | $19.68 | $885,825.00 | (11%) 400.29K to 355.29K | |
| 21-Dec-23 1:38 PM View: | Mills Kenneth T. President and CEO Director | Regenxbio Inc. (RGNX) | 19-Dec-23 | Option Exercise | 45,000 | $3.66 | $164,835.00 | 13% 355.29K to 400.29K | |
| 04-Jan-24 4:22 PM View: | Danos Olivier Chief Scientific Officer | Regenxbio Inc. (RGNX) | 30-Jun-23 | Grant | 1,123 | $16.99 | $19,081.50 | 1% 93.68K to 94.8K | |
| 06-Jun-23 10:00 PM View: | Migausky George V Director | Regenxbio Inc. (RGNX) | 02-Jun-23 | Grant | 3,486 | -- | -- | 116% 3.01K to 6.5K | |
| 06-Jun-23 10:00 PM View: | Stump David C Director | Regenxbio Inc. (RGNX) | 02-Jun-23 | Grant | 3,486 | -- | -- | 116% 3.01K to 6.5K | |
| 06-Jun-23 10:00 PM View: | Bennett Jean Director | Regenxbio Inc. (RGNX) | 02-Jun-23 | Grant | 3,486 | -- | -- | 116% 3.01K to 6.5K | |
| 06-Jun-23 10:00 PM View: | Tasse Daniel Director | Regenxbio Inc. (RGNX) | 02-Jun-23 | Grant | 3,486 | -- | -- | 116% 3.01K to 6.5K | |
| 06-Jun-23 10:00 PM View: | Glucksmann Alexandra Director | Regenxbio Inc. (RGNX) | 02-Jun-23 | Grant | 3,486 | -- | -- | 116% 3.01K to 6.5K | |
| 06-Jun-23 10:00 PM View: | Zachary Jennifer Director | Regenxbio Inc. (RGNX) | 02-Jun-23 | Grant | 3,486 | -- | -- | 58% 6.02K to 9.51K | |
| 06-Jun-23 10:00 PM View: | Karabelas Argeris N Director | Regenxbio Inc. (RGNX) | 02-Jun-23 | Grant | 3,486 | -- | -- | 116% 3.01K to 6.5K | |
| 02-Jun-23 4:12 PM View: | Vasista Vittal Chief Financial Officer | Regenxbio Inc. (RGNX) | 31-May-23 | Option Exercise | 35,000 | $0.85 | $29,750.00 | 19% 180.0K to 215.0K | |
| 05-Jan-23 4:06 PM View: | Christmas Patrick J. Chief Legal Officer | Regenxbio Inc. (RGNX) | 03-Jan-23 | Grant | 67,940 | -- | -- | 296% 22.94K to 90.88K | |
| 05-Jan-23 4:06 PM View: | Danos Olivier Chief Scientific Officer | Regenxbio Inc. (RGNX) | 03-Jan-23 | Grant | 65,930 | -- | -- | 227% 29.08K to 95.01K | |
| 05-Jan-23 4:06 PM View: | Pakola Steve Chief Medical Officer | Regenxbio Inc. (RGNX) | 03-Jan-23 | Sale (Planned) | 3,138 | $22.17 | $69,559.40 | (3%) 105.9K to 102.76K | |
| 05-Jan-23 4:06 PM View: | Pakola Steve Chief Medical Officer | Regenxbio Inc. (RGNX) | 03-Jan-23 | Grant | 90,588 | -- | -- | 528% 17.15K to 107.74K | |
| 05-Jan-23 4:06 PM View: | Christmas Patrick J. Chief Legal Officer | Regenxbio Inc. (RGNX) | 03-Jan-23 | Payment of Exercise | 1,843 | $22.68 | $41,799.20 | (2%) 90.88K to 89.04K | |
| 05-Jan-23 4:06 PM View: | Mills Kenneth T. President and CEO Director | Regenxbio Inc. (RGNX) | 03-Jan-23 | Grant | 54,753 | -- | -- | 18% 309.84K to 364.6K | |
| 05-Jan-23 4:06 PM View: | Danos Olivier Chief Scientific Officer | Regenxbio Inc. (RGNX) | 03-Jan-23 | Payment of Exercise | 2,058 | $22.68 | $46,675.40 | (2%) 95.01K to 92.95K | |
| 05-Jan-23 4:06 PM View: | Vasista Vittal Chief Financial Officer | Regenxbio Inc. (RGNX) | 03-Jan-23 | Grant | 46,174 | -- | -- | 34% 135.16K to 181.33K | |
| 05-Jan-23 4:06 PM View: | Simpson Curran Chief Oper. & Tech. Officer | Regenxbio Inc. (RGNX) | 03-Jan-23 | Grant | 67,945 | -- | -- | 251% 27.12K to 95.06K | |
| 05-Jan-23 4:06 PM View: | Pakola Steve Chief Medical Officer | Regenxbio Inc. (RGNX) | 03-Jan-23 | Payment of Exercise | 1,837 | $22.68 | $41,663.20 | (2%) 107.74K to 105.9K | |
| 05-Jan-23 4:06 PM View: | Mills Kenneth T. President and CEO Director | Regenxbio Inc. (RGNX) | 03-Jan-23 | Payment of Exercise | 9,308 | $22.68 | $211,105.00 | (3%) 364.6K to 355.29K | |
| 05-Jan-23 4:06 PM View: | Vasista Vittal Chief Financial Officer | Regenxbio Inc. (RGNX) | 03-Jan-23 | Payment of Exercise | 1,333 | $22.68 | $30,232.40 | (< 1%) 181.33K to 180.0K | |
| 05-Jan-23 4:06 PM View: | Simpson Curran Chief Oper. & Tech. Officer | Regenxbio Inc. (RGNX) | 03-Jan-23 | Payment of Exercise | 2,076 | $22.68 | $47,083.70 | (2%) 95.06K to 92.98K | |
| 31-Aug-22 6:01 PM View: | Vasista Vittal Chief Financial Officer | Regenxbio Inc. (RGNX) | 30-Aug-22 | Market Sale (Planned) | 2,400 | $30.24 | $72,572.60 | (2%) 137.56K to 135.16K | 7% |
| 08-Aug-22 4:04 PM View: | Vasista Vittal Chief Financial Officer | Regenxbio Inc. (RGNX) | 05-Aug-22 | Sale (Planned) | 17,280 | $35.19 | $608,035.00 | (11%) 154.84K to 137.56K |
